| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to new compounds of general formula III which possess the properties of JAK pathway inhibitors and JAK-kinase inhibitors. In formula III:X is specified in a group consisting of C-Calkyl, amino, halogen, carboxyl, carboxylic acid ester, Calkynyl, substituted tri-C-Calkylsilyl; R represents hydrogen; the cycle A is specified in a group consisting of Caryl, bicycloheptene, five-and sis-member mono- or 10-member bicyclic heteroaryl including 1 to 3 heteroatoms specified in a group of heteroatoms, including N, O or S, and five- or six-member mono- or 10-member bicyclic heterocycle, including 1 to 2 heteroatoms specified in a group of heteroatoms, including N or O; p means 0, 1, 2 or 3; each of Ris independently specified in a group consisting of C-Calkyl, C-Calkyl substituted by 1 to 3 substitutes. The other substitute and radical values are specified in the patent claim.EFFECT: compounds may be used in preparing a therapeutic agent for T-cell mediated autoimmune disease, for treating or preventing allograft rejection in a recipient, for treating or preventing a type IV hypersensitivity reactions, which includes administering the above agent containing the compound according to cl 1-11, in an amount effective to treat the autoimmune disease or the allograft rejection or the type IV hypersensitivity.23 cl, 7 dwg, 12 tbl, 43 ex |
